KEY PEOPLE

Khoso Baluch has over 36 years of experience across global geographies, most recently as CEO and Board member of CorMedix Inc., a publicly-traded US company. Prior to joining CorMedix Inc., Khoso worked for 8 years for the global biopharmaceutical company UCB, notably as Senior Vice President & President European Region. He also worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in General Management, Business Development, Market Access and Product leadership.
Khoso is currently a Board member at Poxel Pharma, a French publicly traded Biotech company. He also sits on the Strategic Advisory Committee for Morningside Biopharma Advisory. Skilled at building strategic partnerships and driving market entry and expansion, Khoso successfully led U.S. and international commercial teams in primary care, specialty, and hospital segments.

Nabil Abadir is a Medical Doctor with over 25 years’ experience in the pharmaceutical and biotechnology industry. He graduated from the Alexandria University Faculty of Medicine in 1983 before joining the life science industry.
His experience includes working in small companies (Ferring Pharma & Clementia) as well as major pharma companies (Novartis, Sanofi, Abbott, Schering Plough & Merck). He led the local medical department as VP Medical for Schering Plough Canada before heading Merck’s Medical Affairs organization for Europe, Canada, Middle East and Africa region based in Switzerland. Nabil then was nominated as the Executive VP for Clementia Pharma, a Canadian start-up biotech company until its acquisition by Ipsen Pharma. Finally, he led the Global Medical Affairs organization for Novartis Gene Therapy. Throughout his career he successfully built and strengthened a number of medical organizations at the local, regional and global level: he created multiple best practices, SOPs, guidelines, asset life cycles, real-life data generation and dissemination plans including Health Economic data to support the pricing and reimbursement of various assets. His extensive experience covers a wide range of therapy areas, including oncology and anti-infectives. He also experienced a number of acquisitions and mergers and participated in multiple business development deals.
Nabil is a strong believer in the importance of data generation and dissemination, education and building a solid network with the scientific community and external stakeholders to ensure the best management and safety of patients as the first and foremost priority.

Florence Séjourné graduated from MINES ParisTech in 1994 with a specialization in biotechnology, and from the University of Illinois in Chicago with a Master’s degree in Bioengineering and Pharmaceutical Sciences in 1996. She started her career managing the biotechnology department of Eurasanté, one of the first French bioincubators, and was in charge of the valorization of regional research and of company creation. Prior to joining Da Volterra in 2008 as President and CEO, Florence co-founded Genfit (Euronext GNFT), a leading biotech company in the field of metabolic and inflammatory diseases, in 1999. As Director of Operations, Business Development and Alliances, and member of the Executive Board, she has greatly contributed to the development of the company, including its successful IPO in 2006. Florence Séjourné brings to Da Volterra the experience of successful entrepreneurial ventures, her ability to build and lead a highly professional R&D organization, to raise private and public funds, and to structure and negotiate agreements with pharmaceutical and biotechnology companies in a highly competitive international environment.
Florence Séjourné also co-founded the BEAM Alliance, an association of more than 70 European biopharmaceutical companies involved in the development of innovative products to fight antibiotic resistance.

After graduating from the École Agronomique de Paris, Jean de Gunzburg became a molecular and cell biologist and, after a successful academic career, he decided to dedicate his experience and know-how to the development of Da Volterra. After obtaining his PhD in 1985 from the University of Paris 7 for work done at the Pasteur Institute in Paris, Jean continued his training with a postdoctoral fellowship at the Whitehead Institute for Biomedical Research (Cambridge). In 1988, he became Director of Research at the CNRS and headed the Inserm Laboratory of Signal Transduction and Oncogenesis at the Institut Curie in Paris until mid-2005. He has published more than 70 articles in international journals in fields ranging from biochemistry and molecular biology to cell biology.

Stéphane Postic, a graduate in finance and management from EM Lyon Business School, has held several finance management positions in large international retail companies such as Kering and Carrefour. He was responsible for the financial reporting and management of several business units in France and in the UK and has acquired a solid experience in profit center management. From April 2002, he has supervised the administrative and financial teams of Genfit (Euronext GNFT) and was in charge of financial and commercial control, general administration, human resources and corporate reporting functions, working closely with the Chief Executive Officer and the Chief Operating Officer. In charge of Genfit’s IPO in 2006, he has acquired a strong experience in biotech financing. He joined Da Volterra in 2008.
Stéphane Postic brings a wealth of technical expertise in finance and business administration as well as strategic advice to the Management team.

Fabien Vitry is a medical graduate from the University of Reims, with a specialization in public health. He holds a postgraduate degree in clinical epidemiology and evaluation of health actions from the Universities of the North-East region. He worked for 5 years as a hospital practitioner at the University Hospital of Reims, where he managed a clinical research unit.
Fabien Vitry has a global experience of more than 15 years in the medical and clinical teams of large pharmaceutical companies (Boehringer-Ingelheim, Servier). He has mainly led clinical development projects in the respiratory, metabolic and oncology fields and has held medical management and project management positions, most recently on an allogeneic CAR-T product in hemato-oncology.
Fabien Vitry brings 20 years of medical experience in innovative clinical development, including oncology, to Da Volterra, and is in charge of elaborating the medical strategy for product candidates, establishing clinical development plans in collaboration with regulatory authorities, and supervising their implementation with his team. He is also responsible for the safety and risk assessment of product candidates and supervises in particular the vigilance and medical information activities.

Karine Bertrand graduated from ESPCI ParisTech (École Supérieure de Physique et Chimie Industrielles) and holds a PhD in Medicinal and Organic Chemistry from the University of Lille. Karine started her career at UCB Pharma and then joined Genfit (Euronext: GNFT) where she held several senior positions (Director of Pharmaceutical and Analytical Chemistry and Development, Director of Strategic Planning and Program Management, and Executive Vice President of Corporate Development).
With more than 20 years of experience in R&D and pharmaceutical project management, she has a broad range of expertise covering the design and operational and technical management of pharmaceutical discovery, development, manufacturing and control programs, as well as the definition and implementation of regulatory strategies for products up to the point where they are marketed as drugs and medical devices. She has negotiated agreements with pharmaceutical raw material manufacturers and suppliers from all continents and has overseen the manufacture of several tons of GMP products throughout her career. Director of Product Development at Da Volterra since 2015, Karine Bertrand is responsible for the design, development and manufacturing of the company’s products. In particular, she is the architect of Da Volterra’s strong scale-up of production capabilities and is now preparing the company’s industrial tool for the first commercialization.

Pierre-Alain Bandinelli graduated from École Polytechnique and MINES ParisTech with a specialization in biology, data analysis and management of innovative companies. He joined Da Volterra at the end of 2009 after working at the Johns Hopkins University (Baltimore, USA) to develop new tissue engineering solutions. He is the author of a dozen publications and posters in pharmaco-economics and medical sciences. Pierre-Alain is also the founder of a company that develops expert software for the aeronautical industry. He is experienced in managing innovative projects and structuring companies. With 10 years of experience in intellectual property, he has coordinated the filing of 14 patent families and has helped obtain about 100 patents in all geographical areas of the world. In charge of partnerships, he has successfully negotiated more than 10 public and private collaborations for a total amount of 30 M€. With a broad knowledge of the development of new high-tech products such as pharmaceuticals, he has played a major role in defining Da Volterra’s orientations and has been at the origin of the creation of the company’s market access, marketing and data mining departments. Under his leadership, the market access strategies for the pipeline products have been clarified and some have already been validated by some of the most demanding authorities. With the other members of the Management team, Pierre-Alain is committed to continuing the transformation of Da Volterra into a pharmaceutical champion in the field of the microbiome and related pathologies.

Frédérique Sablier-Gallis joined the Da Volterra team in 2009 after obtaining her PhD in Pharmacy from the Catholic University of Louvain (Brussels) and a specialization in clinical biology with 3 years of internship in the departments of analytical chemistry (Hôpital Saint Luc, Brussels), microbiology and hematology (Hôpital Sainte Elisabeth, Brussels).
Upon her arrival at Da Volterra, Frédérique Sablier-Gallis successfully set up and organized the activities of the company’s microbiology laboratory. She then took charge of the coordination of the R&D programs in their preclinical phases, in close collaboration with the Chief Scientific Officer, and now manages all the collaborators of the company’s scientific team. With a strong background in medical microbiology, she brings essential expertise in characterizing the protection of the intestinal microbiome of the company’s product candidates, both in non-clinical and clinical studies.

Sakina Sayah-Jeanne holds a PhD in molecular and cellular biology and a specialization in neuroscience (INSERM laboratory and Rouen Faculty of Science). She started her career in 1999 at Innothera as a project manager in charge of screening and identification of drug candidates on a new therapeutic target (neurogenic inflammation). She then joined Genfit (Euronext GNFT) in 2003, where she collaborated with several pharmaceutical partners and quickly became Scientific Director in charge of the transversal management of drug R&D projects in different therapeutic areas (cardiometabolics, neurology).
Sakina Sayah-Jeanne joined Da Volterra in 2011 to coordinate the company’s preclinical activities, before being appointed Director of Transversal and Translational R&D. Working closely with the medical and clinical team, the scientific teams and numerous external experts, her mission is to produce decision support and risk management elements for the efficacy and safety profile of candidate products, scientific and strategic arguments for submission to regulatory agencies, as well as to lead the transversal management of projects. Sakina brings to Da Volterra 20 years of experience in non-clinical, cross-functional and translational R&D, in scientific support of regulatory affairs and development of the company’s portfolio to market.